Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

This investigation has raised concerns about potential legal and reputational ... the approval process for Pfizer’s vaccine candidates. Despite these challenges, Pfizer maintains a Moderate ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE ... rebounded after Wall Street analysts highlighted the significant legal challenges the order would face. The pharmaceutical industry has ...

Pfizer defended the initiative ... this complaint fits a larger wave of legal challenges to diversity programs.

positioning it well for future growth despite recent market challenges. The legal battle began in 2020 when Pfizer accused SK bioscience of infringing on the composition patent of its own vaccine ...

Court revives lawsuit against Pfizer's diversity fellowship Group ... it issued last year holding the organization lacked legal standing to challenge the drugmaker's program in court.

According to InvestingPro data, the company faces significant financial challenges ... ITIL agreed to cover a transaction fee and Pfizer’s legal expenses. Iterum’s CEO, Corey Fishman ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” ...

Over two days, doctors at Harvard-affiliated Brigham and Women’s Hospital, who are leaders in the field, explained the causes of the heart disease and new drugs that could challenge Pfizer’s ...

David Risinger has given his Hold rating due to a combination of factors surrounding Pfizer’s current financial ... stems from projected revenue growth challenges over the next five years ...

Among the many logistical and medical challenges that experts say will have to be overcome when vaccines are ready to roll: Pfizer's shipping boxes, packed with specially formulated dry ice and ...